Newsfeeds - Spark Newswire

1 minute read

Cigna Is Out With A New Coverage Policy Stating That TherapeuticsMD Imvexxy Is Now Covered. (Effective 1/1/24 But Just Disclosed).

Today, 7:27 AM

https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0216_coveragepositioncriteria_vaginal_estrogen_products.pdf

TXMD

1 minute read

Cantor Fitzgerald Reinstates Neutral on TherapeuticsMD, Announces $5 Price Target

By Benzinga Newsdesk

Today, 7:27 AM

Cantor Fitzgerald analyst Louise Chen reinstates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and announces $5 price target.

TXMD

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 7:27 AM

Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock rose 44.2% to $0.29 during Monday’s after-market session. At the close, Novo…

ALLR

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 7:27 AM

Gainers Ambrx Biopharma (NYSE:AMAM) shares increased by 9.3% to $0.57 during Monday’s after-market session. This security traded at…

AMAM

1 minute read

News

TherapeuticsMD Announces $7M Private Placement

By Benzinga Newsdesk

Today, 7:27 AM

TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today that it received a $7 million private

TXMD

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 7:27 AM

Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.

ANPC

1 minute read

TherapeuticsMD Appoints Dr. Brian Bernick And Mr. Mark Glickman As Interim Co-Chief Executive Officers

By Benzinga Newsdesk

Today, 7:27 AM

TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark

TXMD

2 minute read

Earnings

Looking Into TherapeuticsMD’s Return On Capital Employed

By Benzinga Insights

Today, 7:27 AM

According to Benzinga Pro, during Q2, TherapeuticsMD (NASDAQ:TXMD) earned $112.28 million, a 329.05% increase from the preceding quarter. TherapeuticsMD also posted a total of $28.56 million in sales, a 47.73% increase since Q1.

TXMD